GLP-1 Peptide Atlas, by Delfa

CompletedPhase 1

A Study of LY3437943 in Chinese Participants With Obesity Or Overweight

A Multiple Dose Escalation Study in Chinese Participants With Overweight BMI or Obesity to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3437943

Lead sponsor

Eli Lilly and Company

Asset

Retatrutide

Subcutaneous · GLP-1 / GIP / glucagon triple

Listed sites

Recruiting sites

—

Enrollment

actual

Study population

Obesity / overweight, Type 2 diabetes

Key I/E criteria

•BMI 27-40•HbA1c 7-10.5%

Primary endpoint

•Treatment-emergent AEs (any) (Treatment-emergent AEs (any), Serious AEs (any))

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT05548231

Org study ID17954

Secondary IDJ1I-MC-GZBEEli Lilly and Company

Timeline

Milestones

Study first posted2022-09-21actual

Study start2022-10-24actual

Primary completion2023-07-27actual

Study completion2023-07-27actual

Last update posted2023-08-14actual

Assets

Investigational agents

Retatrutide

Study populations

Who this study enrolls

Obesity / overweightType 2 diabetes

Eligibility

Who can enroll

Minimum age20 Years

Maximum age65 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

For All Participants:

•Are native Chinese males or females

•Have a body mass index of ≥27 and ≤40 kilograms per square meter (kg/m²)

•Have not modified diet or adopted any nutritional lifestyle modification for 3 months

•Have stable body weight for the last three months

•Male participants must agree to use contraception during the study and for 4 months afterward and female participants must be woman of nonchildbearing potential

For Type 2 Diabetes Mellitus (T2DM) Participants:

•Have type 2 diabetes for at least 3 months

•Have a glycated hemoglobin (HbA1c) value of ≥7.0% and ≤10.5% and have been treated with diet and exercise alone or a stable dose of metformin for at least 3 months prior to screening

Exclusion criteria

For All Participants:

•Have an average weekly alcohol intake that exceeds 21 units per week (males) and 14 units per week and smoke more than 10 cigarettes, or cigarette equivalent (as determined by investigator), per day

•Have other serious or unstable illnesses

•Have had an episode of severe hypoglycemia

•Current or chronic history of liver disease.

For T2DM Participants:

•Have type 1 diabetes mellitus

•Have uncontrolled diabetes, defined as an episode of ketoacidosis or hyperosmolar state requiring hospitalization

•Any glucose-lowering medications other than metformin within 3 months prior to screening

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Safety / tolerability / PK

3 endpoints

Primary/protocol endpoint

Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration

Time frame:Baseline through Week 20

Treatment-emergent AEs (any)

event count, event

componentsTreatment-emergent AEs (any), Serious AEs (any)

Secondary/protocol endpoint

Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3437943

Time frame:Predose through Day 109

Cmax

concentration, descriptive

Secondary/protocol endpoint

PK: Area Under the Concentration Versus Time Curve (AUC) of LY3437943

Time frame:Predose through Day 109

AUC₀–∞

concentration, descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.